PrimeRFP SCOUT · Federal Contract Recompete Brief

36C25719N0512WAIVED BLOOD testing pt-inr lease&reagents — Roche Diagnostics Corp

Roche Diagnostics Corp holds $245.9M across 1,391 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards under parent V797P5279B. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Jun 30, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

257-Network Contract Office 17 (36C257)

Awarding office

Roche Diagnostics Corp

Recipient

Jun 30, 2024

PoP end

$45K

Obligated

$170K

Potential

325413

NAICS

6640

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Roche Diagnostics Corp — $90

Contract facts

Federal

Contract number36C25719N0512

Also listed as36C257-19-N-0512

Also listed asV797P5279B-36C25719N0512

Agency257-Network Contract Office 17 (36C257)

Awarding office257-Network Contract Office 17 (36C257)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentRoche Diagnostics Corp

CAGE51169

UEIJDMDFEZBYH36

NAICS325413

No full NAICS 325413 intel page yet. Browse NAICS intelligence

PSC6640

Parent IDIQ / IDVV797P5279B

Place of performanceINDIANAPOLIS IN

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startApr 1, 2019

PoP end (current)Jun 30, 2024

Obligated$45K

Current value$133K

Potential value$170K

WAIVED BLOOD TESTING PT-INR LEASE&REAGENTS is a federal award for 257-Network Contract Office 17 (36C257) held by Roche Diagnostics Corp. Estimated value $170K ($45K obligated). Current period of performance ends Jun 30, 2024. Last award drew 1 bidder. Place of performance: INDIANAPOLIS IN.

WAIVED BLOOD TESTING PT-INR LEASE&REAGENTS

Recompete timing

Public

● Past PoP end (782 days ago)

Current PoP ended Jun 30, 2024 (782 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Roche Diagnostics Corp — $245.9M obligated across 1,391 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($245.9M) · all agencies

Department of Veterans Affairs (VA)$154.1M · 63%Department of Defense (DOD)$77.5M · 32%Department of Health and Human Services (HHS)$10.4M · 4%Department of Justice (DOJ)$3.0M · 1%

Open full company profile →

Related awards

Same parent · incumbent

36C26225N0151

CHEMISTRY IMMUNOASSAY SYSTEM CPT

$5.9M

Aug 31, 2026

36C25025N1021

FSS-BPA ROCHE COBAS 4800 REAGENTS, CONSUMABLES, CONTROLS.

$600K

Aug 31, 2026

FA480321F0055

ROCHE COVID TEST KITS

$159K

Aug 31, 2026

36C25025N1000

COBA REAGENTS/CONSUMABLES

$135K

Aug 31, 2026

36C25726P0473

BENCHMARK ULTRA PLUS

$132K

Aug 31, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C25719N0512?

36C25719N0512 (WAIVED BLOOD testing pt-inr lease&reagents) is a 257-Network Contract Office 17 (36C257) award with a potential value of $170K, currently held by Roche Diagnostics Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C257-19-N-0512?

36C257-19-N-0512 is the dashed form of PIID 36C25719N0512 (WAIVED BLOOD testing pt-inr lease&reagents), held by Roche Diagnostics Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C25719N0512?

257-Network Contract Office 17 (36C257) awarded 36C25719N0512 to Roche Diagnostics Corp (potential $170K).

Who is the incumbent on 36C25719N0512?

Roche Diagnostics Corp is the incumbent with $245.9M across 1391 related awards in SCOUT’s public footprint. The current period of performance ends Jun 30, 2024.

When does Roche Diagnostics Corp’s 36C25719N0512 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 30, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Mar 20, 2024